• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Supervision of Medical Device Manufacturing in China – 2022 Regulatory Updates

Supervision of Medical Device Manufacturing in China – 2022 Regulatory Updates

supervision of medical device manufacturing
Monday, 25 April 2022 / Published in Medical Device, News, NMPA Registration in China

Supervision of Medical Device Manufacturing in China – 2022 Regulatory Updates

Supervision of medical device manufacturing in China will be strengthened when a new regulatory measure comes into effect on May 1, 2022.

On March 22, 2022, the National Medical Products Administration (NMPA) published (No.53-2022) the amended version of the Administrative Measures for the Supervision of Medical Device Manufacturing to replace the previous CFDA Order No.7 announced on July 30, 2014.

China Supervision of Medical Device Manufacturing – Key Changes

The key changes about which manufacturers should be aware are summarised by our regulatory experts below.

  • For the application of medical device production licenses and the filing of class I medical device production, information that can be verified online will no longer be required in the dossier submission such as the copy of the business license.
  • The internal review of medical device production license approvals will be reduced from 30 working days to 20 working days.
  • The filing of class I medical device production and the filing of the class I medical device itself can be applied at the same time for both applications.
  • OEM (Original Entrusted Manufacture) manufacturers will be allowed to use the registrant’s certificate to apply for medical device production licenses in China. In the past, medical device production licenses can only be applied by the original manufacturers themselves with their own registration certificate.
  • OEM production will no longer be restricted to one OEM manufacturer only. The “Entrusted Production Management” chapter will be removed from the new measures, but administered in the QMS requirements instead.
  • OEM manufacturers and the registrants will be required to sign the OEM quality agreement specifying the obligations and responsibilities of both sides. Registrants will be responsible for the product quality and safety whilst the OEM manufacturers will be responsible for the production activities.
  • The new measures also specify the responsibilities of registrants when carrying out inspection for cross-province OEM production.

On March 22, 2022, the NMPA issued the amended version of the Administrative Measures for the Supervision of Medical Device Business Operation to replace the previous CFDA Order No.8 announced on July 30, 2014. Read our separate blog post for more information.

On March 24, 2022, the NMPA also published the following two regulatory measures concerning OEM production in China:

  • Catalogue of medical device products to be prohibited from OEM production in China (No.17-2022)
  • Guideline for writing OEM quality agreements in China (No.20-2022)

By Julie Zhang and Jacky Li. If you would like to learn more about supervision of medical device manufacturing in China or our registration and CRO services for medical devices, IVDs, pharmaceuticals, cosmetics or other products, please contact Cisema.

Tagged under: medical device, medical device manufacturing

What you can read next

Cisema Webinar on Medical and Cosmetic Product Certification
New fees, tests and document requirements for DMF registration of APIs
CMDE Analyzes the Typical Issues for Combination Product Registrations

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.